Evogene (NASDAQ:EVGN) Earns Sell Rating from Analysts at StockNews.com

Investment analysts at StockNews.com started coverage on shares of Evogene (NASDAQ:EVGN) in a research report issued to clients and investors on Wednesday. The firm set a “sell” rating on the biotechnology company’s stock.

Separately, Alliance Global Partners reissued a “buy” rating on shares of Evogene in a research report on Friday, March 7th.

Evogene Stock Down 1.1 %

Shares of EVGN stock opened at $1.38 on Wednesday. The stock has a market cap of $7.38 million, a P/E ratio of -0.31 and a beta of 1.28. The company’s fifty day simple moving average is $1.50 and its two-hundred day simple moving average is $1.87. Evogene has a 52 week low of $1.20 and a 52 week high of $9.00.

Evogene (NASDAQ:EVGN) last posted its earnings results on Thursday, March 6th. The biotechnology company reported $0.06 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.72) by $0.78. The firm had revenue of $1.61 million for the quarter, compared to the consensus estimate of $3.63 million. Evogene had a negative net margin of 314.43% and a negative return on equity of 109.05%. During the same period in the previous year, the firm posted ($1.30) EPS.

Institutional Trading of Evogene

An institutional investor recently bought a new position in Evogene stock. Jane Street Group LLC bought a new stake in shares of Evogene Ltd. (NASDAQ:EVGN) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 21,345 shares of the biotechnology company’s stock, valued at approximately $40,000. Jane Street Group LLC owned about 0.40% of Evogene as of its most recent filing with the Securities & Exchange Commission. 10.40% of the stock is owned by hedge funds and other institutional investors.

Evogene Company Profile

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.